Disease-Modifying Potential of BET Inhibitor Pelabresib (CPI-0610) As Demonstrated By Improvements in Bone Marrow Function and Clinical Activity in Patients with Myelofibrosis - Preliminary Data
Year: 2021
Type: conference-abstract
Source: Blood
Authors: Srdan Verstovsek, Mohamed E Salama, John Mascarenhas, Moshe Talpaz, Ruben A. Mesa, Alessandro Vannucchi, Raajit Rampal, Stephen T. Oh, Horatiu Olteanu, April Chiu, Dong Chen, Curtis A. Hanson, Natalia Curto-Garcia, Pietro Taverna, Jike Cui, Oksana Zavidij, Zehua Chen, Gozde Colak, Sergey Efuni, Patricia J Keller, Patrick Trojer, Claire N. Harrison
Institutions: The University of Texas MD Anderson Cancer Center, Mayo Clinic, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, University of Michigan, Mays Cancer Center at UT Health San Antonio, Azienda Ospedaliero-Universitaria Careggi, Memorial Sloan Kettering Cancer Center, Washington University in St. Louis, Guy's and St Thomas' NHS Foundation Trust, Constellation Pharmaceuticals (United States)
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3212699543